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BACKGROUND. The total prostate-specific antigen (t-PSA) in serum measured by PSA 
assays represents the sum of free (f-PSA) and PSA complexed with al-antichymotrypsin.
The f-PSA/t-PSA (F/T) ratio in prostate cancer (PCA) patients is lower than in patients 
suffering from benign prostatic hyperplasia (BPH). This review summarizes the currrent 
literature on the clinical relevance of measurement of the F/T PSA ratio.
METHODS. Discussed are; physiology of PSA, assays for t-PSA and F/T ratio, factors which 
bias the F/T PSA ratio, use of F/T PSA ratio in the detection of PCA, correlation with 
histological features, and pathological stage.
RESULTS. Using the F/T ratio in the intermediate t-PSA range, a reduction of approximately 
30% in biopsies can be accomplished in the detection of prostate cancer.
CONCLUSIONS. The F/T PSA ratio could become a valuable tool in the differentiation of 
BPH from PCA. To accomplish this goal, an international standardization not only for the 
t-PSA measurement but also for the F/T PSA ratio must be a priority for manufacturers of 
PSA assays. © 1996 Wiley-Liss, Inc.
KEY WORDS: prostate-specific antigen, free, complexed, antichymotrypsin, benign
prostate hyperplasia, prostatic carcinoma
has recommended yearly determinations of PSA 
combined with DRE for men above the age 50 years 
for the purpose of detecting prostate cancer at an 
early stage [5]. However, because PSA is a protein 
expressed in the normal prostate gland, PSA is or­
gan-specific but not disease-specific. Especially in the 
intermediate range of serum PSA (2.0-20.0 ng/ml), 
there is a great overlap between serum PSA values of 
patients with benign prostate hyperplasia (BPH) and 
PCA. In this range, a high percentage of unnecessary 
biopsies is performed when the criterion for taking 
biopsies is a PSA elevation above normal reference 
range. To enhance the accuracy of PSA in the inter-
Address reprint requests to M.P. van Iersel, Department of Urol­
ogy, University Hospital Nijmegen "St. Radboud/' P.O. Box 9101, 
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INTRODUCTION
Prostate cancer (PCA) is the second leading cause 
of cancer death in men [1]. Fortunately, after curative 
radical prostatectomy, men with organ-confined dis­
ease have a survival rate that is equal to men without 
PCA [2], High incidence and possibility for curative 
treatment are important prerequisites for a possible 
value of screening for PCA. Further conditions that 
have to be fulfilled for the application of a test in a 
screening population are tolerability, accuracy, and 
acceptable cost. An accurate blood test would meet 
these requirements. Papsidero et al. [3] were the first 
to report high serum concentrations of prostate-spe­
cific antigen (PSA) in patients with PCA. Since then, 
several studies have shown that the determination of 
serum PSA is more reliable to predict PCA than either 
transrectal ultrasound (TRUS) or digital rectal exam­
ination (DRE) alone [4]. The American Cancer Society
© 1996 Wiley-Liss, Inc
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mediate PSA range, Benson et al. [6] introduced PSA 
density (PSAD), representing PSA divided by gland 
volume. They advocated a cutoff level for PSAD of 
0.15 in patients with PSA between 4.0-10.0 ng/ml. 
Several authors have raised objections against the use 
of this cutoff value [7,8]. PSA velocity (PSAV), the 
change in serum PSA over time, was subsequently 
introduced by Carter et al. [9]. They found a PSAV 
<0.75 ng/ml/year to be indicative for the presence of 
PCA. Because of the high intrapatient variability in 
PSA measurements, the calculation of PSAV must be 
done using PSA measurements taken at least 1 year 
apart and with at least three separate measurements 
[10]. In summary, the clinical value of PSAD and 
PSAV in differentiating between BPH and PCA in the 
intermediate PSA range is disputed. Based on the 
observation that the aging prostate increases in size, 
resulting in a rise in PSA production [11], Oesterling 
et al. [8] constructed age-specific reference ranges for 
PSA. Using a different reference range for each age- 
decade rather than regarding an upper limit of 4.0 
ng/ml as normal for all ages, the accuracy of PSA 
could thus be enhanced. However, in a trial involving 
6,630 men conducted by Catalona et al. [12], no dif­
ference was found in accuracy using age-specific ref­
erence ranges for PSA.
FREE-TO-TOTAL PSA RATIO, 
A NEW PARAMETER
In serum, PSA forms complexes with al-antichy- 
motrypsin (ACT) and several other protease inhibi­
tors. The total PSA (t-PSA) measured by PSA assays 
represents the product of reactivity with free PSA (f- 
PSA) and PSA complexed to ACT (ACT-PSA). The 
proportion of t-PSA that forms a complex with ACT 
appears to be higher in patients suffering from PCA. 
As a result, the f-PSA/t-PSA (F/T) ratio in PCA pa­
tients is lower than in BPH patients. The establish­
ment of a reference range of this new parameter in 
men with BPH and in men with PCA could give the 
practicing urologist a valuable new tool in the differ­
entiation of BPH from PCA in the intermediate PSA 
serum range (2-20 ng/ml). This review summarizes 
the literature about the clinical use of the F/T ratio of
PSA.
PHYSIOLOGY OF PSA
Originally identified in seminal plasma in 1971 by 
Hara et al. [13], PSA was first isolated from prostatic 
tissue by Wang et al. in 1979 [14]. PSA is also named 
human glandular kallikrein 3 (hK3) and shows a re­
stricted chymotrypsin-like specificity. It is produced 
only in the prostatic secretory epithelium. Secreted in 
the seminal plasma at concentrations in the range of
0.2-5.0 mg/ml [15], it plays a role in the liquefaction 
of semen through hydrolysis of semenogelin [16]. In 
vitro, proteolytic active PSA slowly forms stable com­
plexes with several extracellular pro tease inhibitors 
[17]. In vivo, the release of active PSA in intercellular 
fluids or blood plasma also results in inactivation of 
enzymatic activity [18], PSA occurs in serum in dif­
ferent forms: free PSA (f-PSA, MW (molecular 
weight) 30 kDa), PSA bound to alpha-2-macroglobu- 
lin (A2M-PSA), MW 780 kDa, and PSA bound to al- 
pha-l-anti-chymotrypsin (ACT-PSA), MW 90 kDa 
(Fig. 1). A2M and ACT are extracellular protease in­
hibitors, referred to as serpins. PSA molecules which 
form a complex with A2M are engulfed by this pro-^  
tein, resulting in sterical shielding of all its epitopes. 
The lack of exposure of epitopes therefore prevents 
the detection of A2M-PSA by PSA assays. On the 
other hand, ACT does not cover all epitopes of the 
PSA molecule. Whereas A2M is the major binder of 
PSA when it reaches circulation [19], in 1991 Lilja et 
al. [20] showed that ACT-PSA is the predominant 
immunoreactive form in serum. A smaller immuno- 
reactive fraction (5-30%) occurs as f-PSA; most likely 
this represents an enzymatically inactive form of the 
enzyme [20,21]. The proportion of f-PSA in serum 
does not correlate with the concentration of t-PSA nor 
with that of ACT [22],
Similarity to Other Glandular Kallikreins
The amino-acid sequence of PSA is closely similar 
to those of hKl and hK2 (77% sequence identity) [23]. 
In 1995, hK2 was isolated from seminal fluid by 
Dephertes et al. [24], but its function remains un­
known. The extensive similarity suggests that PSA 
immunoassays may crossreact with hK2 to a various 
extent. Using 25 different monoclonal antibodies 
(Moabs) in all possible two-site combinations (cap­
ture- and detection-Ab), Piironen et al. [25] con­
structed epitope maps on PSA and hK2< Of the 25 
Moabs, seven showed crossreaction with hK2. Only 
low concentrations of hK2 were measured in serum 
samples as compared to PSA. However, until any 
influence of PSA measurement in serum by occasion­
ally elevated hK2 concentrations is excluded, proper 
selection of Moabs remains essential to avoid cross­
reactivity with hK2 in clinical assays.
Metabolism of PSA
The metabolism of PSA is largely unknown, A pi­
lot study performed by Agha et al. [26] indicates that 
the main site of metabolism of PSA is in the liver. 
Clearance data from studies measuring serum PSA 
after radical prostatectomy indicate a two-compart­
ment model for f-PSA elimination, with an initial
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Fig. I . Schematic representation of the two major protease inhibitors in serum, A2M and ACT. 
Also indicated is local production of ACT in the prostate by prostatic tumor and production of 
nicked form of PSA (PSA-ni) by BPH.
half-life of approximately 2-3 hr for the first 4 hr after 
removal of the gland, followed by a half-life of ap­
proximately 20-25 hr thereafter [27]. This is shorter 
than the half-life of t-PSA, which has been reported 
to be 2-3 days [11],
ASSAYS FOR DETERMINATION OF PSA 
Assays for t-PSA
The presently used commercial assays for the mea­
surement of PSA are double-determinant, "sand- 
wich-type," noncompetitive immunoassays. Except 
for the IMx PSA assay (Abbott, Abbott Park, IL) 
which is a monoclonal-polyclonal assay, these sand­
wich assays make use of a monoclonal capture anti­
body and a monoclonal detection antibody. The cap­
ture Moab is fixed with its constant region to a solid 
phase (e.g., a tube or bead). It "captures" with its 
variable region the protein measured, in this case 
PSA, from the added serum by binding to a unique 
epitope. The detection (or tracer) Moab then binds to 
a different, structurally unrelated epitope. The 
amount of bound PSA is measured by chemilumines- 
cence, fluorescence, radiation, or an enzymatic reac­
tion of a label that is chemically bound to the detec­
tion antibody. If the label is an isotope, the method is 
called IRMA (immunoradiometric assay). For enzyme 
or fluorescent labels, it would be called IEMA (immu- 
noenzymetric assay) or IFMA (immunofluorometric 
assay).
Assays for Simultaneous Determination of Free 
and Total PSA
New assays are developed which give simulta­
neous measurement of different molecular forms of
PSA in serum, giving separate results for two forms 
of PSA and also the ratio between them. This dual 
measurement is made possible by utilizing chelates of 
lanthanide metals, which have mutually exclusive 
light-emission spectra and which are measured using 
time-resolved fluorometry. Depending on the Moabs 
used, t-PSA, f-PSA, or ACT-PSA can be measured. 
With these measurements, either the ACT-PSA/t-PSA 
(C/T) or the f-PSA/t-PSA (F/T) ratio can be deter­
mined. Pioneering work was done by Stenman et aL 
in 1991 [21], who by using an anti-ACT-detecting an­
tibody developed an assay specific for ACT-PSA in 
serum (Fig. 2a). They showed that the C/T ratio is 
higher in patients with PCA than in patients with 
BPH. This was confirmed by Wood et al. [28], Chris- 
tensson et al. [22], and Stamey et al. [29]. Theoreti­
cally, the F/T ratio equals 1 minus the C/T ratio. This 
would indicate that measurement of the F/T ratio 
would give no additional information to the measure­
ment of the C/T ratio. However, assays of the ACT- 
PSA complex can severely overestimate the concen­
tration of ACT-PSA in serum because of nonspecific 
adherence of ACT or cathepsin-G complexed to ACT 
to the solid phase of the assay [30], proportionally 
more so at lower concentrations of PSA. Instead of 
measuring ACT-PSA with an anti-ACT antibody, it is 
possible to selectively measure f-PSA using an anti­
body against an epitope which is obscured after com­
plex formation to ACT (Fig. 2b). The accuracy of 
f-PSA assays in comparison with assays of the ACT- 
PSA complex suggest that better discrimination is ob­
tained by using the F/T instead of the C/T ratio 
[22,30].
The reason for the relatively low F/T PSA ratio in 
prostate cancer patients is unknown. ACT is pro-
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a detAb-total detAb-total
detAb-ACT
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b detAb-total detAb-total
Fig. 2. a: Dual assay for detection of t-PSA and c-PSA. Solid 
phase, beads or test tube on which the capture Moab (capAb) is 
attached. ACT, alpha-l-antichymotrypsin from serum sample com- 
plexed to PSA. DetAb-total, antibody in assay which reacts with 
epitope not obscured by complex formation of PSA with ACT.
duced in the liver and circulates in the blood at a 
104-105-fold molar excess compared to PSA, Bjork et 
al. [31] showed that besides the liver, ACT is also 
produced by the normal prostate and prostate carci­
noma cells but not by BPH cells. They stated that 
complex formation between PSA and ACT occurs lo­
cally at the point of secretion. In Bostwick et al. [32],
DetAb-ACT, Moab in assay which reacts with epitope on alpha-1 - 
antichymotrypsin. b: Dual assay for detection of t-PSA and f-PSA< 
DetAb-free, Moab in assay which reacts with epitope which is 
obscured after complex formation of PSA with ACT.
the difference between ACT-stained cells in benign 
epithelium and carcinoma was modest (40% com­
pared to 48%). Igawa et al. [33] found a significantly 
h itte r proportion of cells immunostaining for ACT in 
tissue from BPH compared to that from prostate can­
cer. Another explanation for the low F/T ratio in pa­
tients with PCA compared to BPH could lie in the
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observation that PSA aspirated from BPH nodules oc­
curs mainly in the "nicked-form" (PSA-ni) [34], This 
form of PSA has multiple internal proteolytic cleav­
ages. Because of these alterations, PSA-ni may have a 
different three-dimensional structure from that of 
seminal fluid PSA. It has lower chymotrypsin-like ac­
tivity than PSA from seminal plasma, but still has 
affinity to the protease inhibitors ACT and A2M. Of 
the nicked form, 4-19% complexed with ACT in 
vitro, whereas 54-67% reacted with A2M in a study 
by Leinonen et al. [19]. Overall, the nicked form 
seems to complex to a lesser degree as compared with 
PSA without cleavages. It is still unclear whether the 
lower enzymatic activity of BPH-PSA or the local pro­
duction of ACT by PCA cells explains the higher F/T 
ratio in BPH patients. The finding that BPH-PSA is of 
a specific molecular structure could imply a possible 
production of specific Moabs against this nicked form 
of PSA. In this way, assay kits could be developed 
with a selective affinity for BPH-PSA, and these may 
prove useful in the discrimination between PCA and
BPH.
INFLUENCE OF F/T PSA RATIO ON T-PSA 
ASSAY READINGS
One of the reasons that different assays for serum 
t-PSA have failed to produce the same PSA values on 
identical specimens is a variability in affinity of the 
detection antibodies to either f-PSA or ACT-PSA [29]. 
A t-PSA assay must be accurate independent of the 
relative amounts of free and complexed PSA in dif­
ferent patient samples. Antibodies used for a t-PSA 
assay should recognize an epitope on the PSA mole­
cule that is not shielded after complex formation to 
ACT, as this would result in preferential binding to 
free PSA. Brawer et al. [35] demonstrated signifi­
cantly lower t-PSA readings in sera when analyzed 
with the IMx (Abbott Laboratories, Abbott Park, IL, 
USA) t-PSA assay as compared to the Tandem Hy- 
britech (Hybritech Inc., San Diego, CA, USA) t-PSA 
assay. The IMx bias appeared to be highly correlated 
with the proportion of f-PSA, This may be the result 
of the presence of a subpopulation of antibodies in 
the (polyclonal-monoclonal) IMx assay that binds to 
the same epitope of PSA as that to which ACT binds. 
The response of such a t-PSA assay which is depen­
dent on the F/T ratio is called "skewed." This in con­
trast to a t-PSA assay with an equimolar response, in 
which the results are independent of the F/T ratio. 
The clinical implication of this finding is that when 
compared to the Hybritech assay, serum specimens 
measured with the IMx assay are less likely to exceed 
a certain cutoff value for t-PSA, and when they do, 
this will be more often due to a high F/T ratio. This is
the case in benign conditions, resulting in the ten­
dency of an inferior diagnostic capacity to differenti­
ate BPH from PCA. Mean measured concentrations 
in identical serum samples may differ up to 36% be­
tween different t-PSA assays [36]. Interpreting t-PSA 
concentrations therefore requires awareness of the 
applied method and accurately determined reference 
ranges, Efforts to reach an international standard for 
measurements of PSA are currently being deter­
mined by Chen et al. [37]. Besides a careful selection 
of antibodies, a universal calibrator for the construc­
tion of the response curve, using a combination of 
90% PSA-ACT complex with 10% f-PSA, is recom­
mended [36].
FACTORS THAT CAN BIAS MEASUREMENT OF 
F/T PSA RATIO 
Prostatic Manipulations
Many studies have been performed to investigate 
the effect of various manipulations of the prostate on 
t-PSA serum level. After cystoscopy, no significant 
change is seen in the serum t-PSA level [38]. After 
prostate biopsies and after transurethral resection of 
the prostate (TURP), the median serum t-PSA rises, 
respectively, to 7.9 ng/ml and 5.9 ng/ml [38]. The re­
sults of these studies do not necessarily have to be 
transferable to measurement of f-PSA and the F/T 
PSA ratio. Glenski et al. [39] showed that DRE does 
not influence serum t-PSA, whereas Collins et al. 
[40], for instance, found a significant F/T ratio in­
crease of 0.16 after DRE. In this study, the F/T ratio 
rose 0.20 after biopsy, and no significant change was 
found after cystoscopy. Hershman et al. [41] de­
scribed a rise in F/T ratio after ejaculation. In view of 
the facts that in semen the ratio of f-PSA is much 
higher than in serum [15] and that the rise of t-PSA in 
men with prostatitis is caused by a disruption of the 
normal physiological barriers to PSA between ductal 
lumen and stroma in prostatic tissue [42], a relatively 
higher rise in f-PSA after prostatic manipulations 
could be caused by leakage of f-PSA originating from 
the intraluminal compartment after trauma of the 
basal membrane.
Stability of PSA After Venesection
The stability in daily laboratory practice of the F/T 
ratio after venesection might be different from that of 
t-PSA. Woodrum et al. [43] reported a stable F/T ratio 
when serum was processed within 3 hr of venesec­
tion, and stored at a maximum of -20°C during a 
6-month period, for at least five freeze-thaw cycles. 
Serum which was stored at 4°C or processed 8 hr after 
blood draw showed a significant decrease in f-PSA.
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selection of candidates for prostate biopsies in a 
screening population. In the study of Smith et aL 
[63], approximately 40% of biopsies could have been
USE OF F /T  RATIO IN DETECTION OF 
PROSTATE CANCER
Using the F/T ratio, accuracy in the diagnosis of 
P C A  can be enhanced [22]. In 422 randomly chosen 
m e n  with no clinical signs of PCA, the lower limit of 
n o rm a l (95th percentile) of the F/T PSA ratio was 
f o u n d  to be 0.15 [44]. This ratio was constant for men 
b e tw e e n  age 40-79 years. In a study in which no 
restrictions were made on the basis of PSA levels, 
K le e  et al. [45] found that the area under the receiver- 
operating curve (AUC) for the F/T ratio was less than 
o r  equal to the AUC for the total PSA for all age 
g ro u p s. (In a ROC (Receiver operator characteristic) 
c u r v e , the x-axis represents 1 minus specificity, and 
t h e  y-axis represents sensitivity. An AUC of 0.5 rep­
r e se n ts  a noninformative test, and an AUC of 1.0 
represents a perfect test.) The additional predictive 
p o w e r  imparted by the measurement of f-PSA was 
v e r y  small (AUC rose 0.02) and only present in the 
a g e  group between 50-70 years, This indicates that a 
p o ssib le  gain in  clinical differentiation between BPH 
a n d . PCA may only be present in the intermediate 
P S A  range, and that determination of the F/T ratio 
ca n n o t replace t~PSA measurement.
F/T Ratio in the Intermediate t-PSA Range
A n overview of several studies performed on the 
capability of the F/T ratio to differentiate between 
B P H  and PCA in  the intermediate PSA range is given 
i n  Table I. Compared to measurement of t-PSA only, 
m easurem ent o f the F/T ratio in studies performed by 
v a n  Iersel et al. [66] (Fig. 3), Oesterling et al. [58] and 
Sagalow sky et al. [59] showed an increase of AUC of, 
respectively, 0*51 to 0.68, 0.53 to 0.73, and 0.52 to 0.72 
f o r  discrimination between BPH and PCA in the in­
term ediate t-PSA range. This means that in this PSA 
ra n g e , differentiation between BPH and PCA using 
t h e  t-PSA values is not significantly better than by 
ch an ce (AUC =  0.5), and that by using the F/T ratio, 
a  fair improvement in this differentiation can be 
m a d e . Petteway et al, [62] measured the F/T for two 
different assays in the same group of patient sera. 
T h e y  concluded that different ratios of F/T PSA are 
necessary to achieve comparable sensitivities. This 
m u s t  be taken into consideration when extrapolating 
find ings from one assay to another. As can be seen in 
T able I, a cutoff value for the F/T ratio in the range of
0 .17-0 .25  gives a sensitivity of approximately 90%, 
w h ile  a specificity of 20-45% is reached. Physician 
j udgm ent m ust be involved in choosing F/T ratio cut­
o f f ,  since one must choose between increased cancer 
detection rate (sensitivity) and increased biopsy rate 
(specificity), as evidenced in Table I. The final goal is 
t o  determine if F/T ratio is an accurate test for the
avoided while maintaining a 90% sensitivity for the 
presence of prostate cancer. The percentage of saved 
biopsies will vary among different studies according 
to the difference in prior probability of cancer inci­
dence. An alternative approach was brought forward 
by Flemming et al. [46], who in a study on cost-effec­
tiveness of screening tests for prostate carcinoma 
found the cost per life-year saved when biopsying all 
screenees was equal when only biopsying according 
to the outcome of DRE and serum PSA. However, 
most men are probably even more reluctant to un­
dergo a routine prostate biopsy, as women are for 
having a cervical smear done. Consequently, the lack 
of tolerability to the screenees most likely will prevent 
this approach from gaining acceptance.
FREE PSA DENSITY
In 200 patients including 100 biopsy-proven PCA 
cases, Yemoto et al. [47] measured f-PSAD and 
t-PSAD. Mean t-PSAD was 0.23 and 0.15 for PCA and 
BPH patients, respectively. Mean f-PSAD was 0.026 
and 0.025 for PCA and BPH patients, respectively. 
They suggested that cancer increases the complexed 
form of PSA in serum much more significantly than 
prostate volume increases the f-PSA in serum. Look­
ing at these data, it seems that the difference in 
t-PSAD between PCA and BPH patients is mainly the 
result of a difference in ACT-PSA density. By using 
ACT-PSAD instead of t-PSAD, the accuracy of PSAD 
in differentiating between PCA and BPH in the inter­
mediate PSA range might be enhanced. A similar ad­
vantage might be found using F/T velocity instead of 
t-PSA velocity.
CORRELATION OF PSA VALUES WITH 
PATHOLOGICAL STAGE 
t-PSA and Stage
Patients with preoperative t-PSA levels below 10 
ng/ml have a negligible risk for a positive bone scan 
[48]. Bleustein et aL [49] demonstrated in a retrospec­
tive study that 406 of 1,632 patients with clinically 
localized disease may be spared pelvic lymph node 
dissection when PSA is used in combination with lo­
cal clinical stage and primary Gleason grade. The 
combination they used yielded a false-negative rate of 
3%. Concerning organ confinement of the tumor, the 
significant overlap in preoperative PSA values pre­
cludes any useful predictive information for the indi­
vidual patient.
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TABLE J* Overview of Studies in Differentiation of Prostatic Cancer and BPH Using Assays for Simultaneous
Measurement of f-PSA and t-PSA*
Authors t-PSA PCA/BPH Cutoff F/T Sensitivity Specificity Population Assay
Elgamal et al. [57] 3-15 37/48 0.18 95 95 re Tic 1
32/48 0.18 88 78 re^T2
Oesterling et al. [58] 2-20 188/248 0.18 80 45 ni 2
0.20 87 37
0.22 89 25
0.24 94 19
Sagalowsky et al. [59] 4-20 23/19 0.11 42 88 Pr 3
0.15 74 75
0.18 84 38
Saito et al. [60] 0-20 80/190 0.16 69 72 pr ni
Reissigl et al. [61] >4 45/101 0.18 75 48 pr ni
0.20 90 37
P ette way et al. [62] 0-10 29/138 0.23 90 45 re 4
0.30 93 30
0.33 100 25
Petteway et al. [62] 0-10 29/138 0.25 90 26 re 3
0.26 93 22
0.31 100 7
Smith et al. [63] 4-10 50/63 0.20 90 38 pr 3
Marley et al. [64] 2.5-20 149/112 0.26 90 19 ni 5
Van Cangh et al. [65] ni 163/290 0.10 41 96 ni 3
0.15 75 82
0.17 82 76
0.20 88 60
0.25 96 36
Iersel et al.** 4-10 50/216 0.18 70 54 re 3
0.25 90 25
Partin et al. [66] 4-10 88/47 0.17 90 46 pr 3
0.20 91 28
0.25 100 14
*t~PSA, range of t-PSA in study; n, number of cases histopathologically proven as respectively PCA and BPH; cutoff, F/T ratio below which 
cases were destined as BPH and above which cases were destined as having PCA; re, retrospective; pr, prospective. Assays: 1, Centrocor; 
2, AxSYM, Abbott; 3, Tandem-R, Hybritech; 4, Dianon; 5, free with DPC-Immulite and total with TOSOH; ni, not indicated. 
’‘"’’Unpublished data.
F/T Ratio and Stage
Several studies have been performed to investigate 
whether the correlation of pathological stage with 
preoperative F/T ratio is superior to the correlation 
with t-PSA. In retrospective studies performed by 
Hendricks et al. [50] and Lerner et al. [51], the F/T 
ratio was measured of 70 and 178 men, respectively, 
who underwent a radical prostatectomy. They con­
cluded that the PSA F/T ratio could not predict 
whether PCA has spread beyond the prostate gland 
at time of prostatectomy. Prospective studies carried 
out by Partin et al. [52] and Graefen et al. [53] in 288 
and 53 men, respectively, brought the same result. In 
a study of 33 patients who underwent radical pros­
tatectomy as a result of a screening program, Ar­
cangeli et al. [54] found that F/T ratio <0.14 signifi-
cantly correlated with a higher stage (P 0.05).
Regarding the limited number of cases included in 
the latter study, the outcome of the former studies 
suggests that F/T ratio provides no additional infor­
mation on the prediction of pathological stage for 
men with clinically localized prostate cancer.
PSA Expression in Cells in Peripheral Blood
A future, better predictor for pathological stage 
might be PSA expression in cells in the peripheral 
blood. These can be detected by a PSA reverse tran- 
scriptase-polymerase chain reaction (RT-PCR) assay. 
Israeli et al. [55] concluded from their study that PSA 
expression is highly specific for the presence of pros­
tate cancer. So far, PSA RT-PCR assays have failed to 
give additional prognostic information about the 
pathologically determined stage [56], Also, as cells 
circulating in the peripheral blood do not necessarily
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h a v e  the capability to form solid metastases, the clin- have a tremendous cost-savings potential The F/T
ic a l significance of the detection of circulating cancer 
cells remains to be assessed.
CORRELATION OF F/T RATIO WITH 
HISTOLOGICAL FEATURES: GLEASON GRADE, 
PERCENTAGE OF CANCER, AND DNA PLOIDY
No correlation was found between F/T ratio and 
Gleason grade in the studies by Graefen et al. [53] 
an d  Lerner et al. [51], whereas Arcangeli et al. [54] 
found that F/T ratio <0.14 was significantly corre­
lated with a higher Gleason grade and high percent-
ratio seems to facilitate the differential diagnosis of 
PCA and BPH in this t-PSA range, saving approxi­
mately 30% of unnecessary biopsies. In this respect 
an international standardization of t-PSA measure­
ments and of assays for the determination of F/T ratio 
would be most welcome. This would not only help  
the patients and physicians with a better differentia­
tion between BPH and PCA, but would also help the  
manufacturers of PSA-assays in obtaining acceptance 
of the determination of F/T ratio for use in screening
programs
a g e  of cancer (P 0.05).
The use of the outcome of pathology on the basis 
o f  performed biopsies as a gold standard is not per­
fect. As reported earlier by several groups, false-neg- 
ative results and an underestimation of Gleason 
grade are common in the pathologic evaluation of 
biopsies. To further evaluate a possible relationship 
between tumor volume and Gleason grade, a study 
o n  preoperative F/T PSA ratios must be performed in 
patients undergoing radical prostatectomy. No rela­
tionship between DNA ploidy and F/T ratio was ob­
served by Lerner et al. [51].
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